Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

International Journal of Clinical Oncology

Volumn 18, Issue 5, 2013, Pages 884-889

  Yasuda, Yosuke ^a   Saito, Kazutaka ^b   Yuasa, Takeshi ^a   Kitsukawa, Shinichi ^a   Urakami, Shinji ^a   Yamamoto, Shinya ^a   Yonese, Junji ^a   Takahashi, Shunji ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Metastatic renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNOTHERAPY; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHILIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 84886096714     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0454-0     Document Type: Article

References (25)

1. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115-124
2. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356:125-134
3. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111
4. Rini BI, Halabi S, Rosenberg JE et al (2008) CALGB 90206: a phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in metastatic renal cell carcinoma. Presented at the genitourinary cancers symposium, San Francisco, CA
5. Palmer PA, Vinke J, Philip T et al (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475-480
6. Negrier S, Escudier B, Gomez F et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13:1460-1468
7. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
8. Atzpodien J, Royston P, Wandert T et al (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88:348-353
9. McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90:215-219
10. Heys SD, Ogston KN, Simpson WG et al (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int J Oncol 13:589-594
11. Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18:146-150
12. Bromwich E, McMillan DC, Lamb GW et al (2004) The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91:1236-1238
13. Casamassima A, Picciariello M, Quaranta M et al (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173:52-55
14. Ramsey S, Lamb GW, Aitchison M et al (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109:205-212
15. Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145-1153
16. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
17. Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543-550
18. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794-5799
19. Saito K, Kihara K (2010) Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 10:1979-1989
20. Saito K, Kihara K (2011) C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8:659-666
21. Komai Y, Saito K, Sakai K et al (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99:77-80
22. Tatokoro M, Saito K, Iimura Y et al (2008) Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 180:515-519
23. Iimura Y, Saito K, Fujii Y et al (2009) Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181:1004-1012
24. Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607-610
25. Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 35:97-105